Type III, IV, and VI Collagens Turnover in Systemic Sclerosis - a Longitudinal Study.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 04 2020
28 04 2020
Historique:
received:
24
01
2020
accepted:
08
04
2020
entrez:
30
4
2020
pubmed:
30
4
2020
medline:
7
1
2021
Statut:
epublish
Résumé
Tissue turnover, especially in the skin, is altered in systemic sclerosis (SSc), leading to tissue accumulation. The objective was to examine type III, IV, and VI collagens turnovers in SSc and investigate longitudinal alterations in relation to modified Rodnan Skin Score (mRSS). We included patients fulfilling the 2013 ACR/EULAR criteria for SSc (limited cutaneous [lcSSc, n = 20], diffuse cutaneous SSc [dcSSc, n = 23]) and healthy controls (HC, n = 10). Biomarkers of type III, IV, and VI collagens formation (PRO-C3, PRO-C4, PRO-C6) and degradation (C3M, C4M, C6M) were measured in serum. The fibrotic index of the individual collagens (FICol) were calculated. The fibrotic index of type III and VI collagens (FICol3 and FICol6) were increased in dcSSc compared to lcSSc (FICol3: 1.4 vs. 0.8, P = 0.0001; FICol6: 1.2 vs. 0.9, P = 0.03). The fibrotic index of type IV collagen (FICol4) was not different between the groups but was 1.5 times higher than HC (HC: 6.9, lcSSc 10.4, dcSSc: 10.5). Both FICol3 and FICol6 correlated with mRSS with rho's of 0.59 (P < 0.0001) and 0.35 (P = 0.04). Furthermore, FICol3 steadily decrease over the disease course. Examining collagen turnover and specific collagens could be beneficial in following patients' skin fibrosis and possibly identifying progressors.
Identifiants
pubmed: 32346065
doi: 10.1038/s41598-020-64233-8
pii: 10.1038/s41598-020-64233-8
pmc: PMC7188682
doi:
Substances chimiques
Collagen
9007-34-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7145Références
Exp Dermatol. 2015 Jun;24(6):401-6
pubmed: 25712746
J Invest Dermatol. 2016 Jan;136(1):74-83
pubmed: 26763426
J Rheumatol. 1988 Feb;15(2):202-5
pubmed: 3361530
PLoS One. 2013 Dec 23;8(12):e84934
pubmed: 24376856
Biomarkers. 2019 May;24(3):249-254
pubmed: 30457356
Clin Biochem. 2010 Jul;43(10-11):899-904
pubmed: 20380828
Arthritis Res Ther. 2007;9(5):R85
pubmed: 17784951
Am J Med Sci. 2014 Oct;348(4):331-6
pubmed: 24853818
Am J Transl Res. 2013 Apr 19;5(3):303-15
pubmed: 23634241
PLoS One. 2015 Dec 07;10(12):e0144525
pubmed: 26641456
PLoS One. 2011;6(9):e24753
pubmed: 21935455
Biomarkers. 2019 Jun;24(4):373-378
pubmed: 30821519
PLoS One. 2018 Dec 3;13(12):e0207324
pubmed: 30507931
N Am J Med Sci. 2012 Jan;4(1):1-8
pubmed: 22393540
J Dermatol. 2017 Feb;44(2):167-172
pubmed: 27568491
Nat Rev Dis Primers. 2015 Apr 23;1:15002
pubmed: 27189141
J Invest Dermatol. 1989 Apr;92(4 Suppl):61S-77S
pubmed: 2649616
PLoS One. 2013 Aug 22;8(8):e71050
pubmed: 23990924
Ann Rheum Dis. 2013 Nov;72(11):1747-55
pubmed: 24092682
Arthritis Rheum. 1990 Dec;33(12):1829-35
pubmed: 2261003